Clinical trials update from the American Heart Association 2007: CORONA, RethinQ, MASCOT, AF-CHF, HART, MASTER, POISE and stem cell therapy

European Journal of Heart Failure

Volumn 10, Issue 1, 2008, Pages 102-108

  Cleland, John G F ^a   Coletta, Alison P ^a   Abdellah, Ahmed Tageldien ^a   Cullington, Damien ^a   Clark, Andrew L ^a   Rigby, Alan S ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Heart failure; Randomised controlled trials

Indexed keywords

METOPROLOL; PLACEBO; ROSUVASTATIN;

ARTICLE; ARTIFICIAL HEART PACEMAKER; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIAL; DEATH; ECHOCARDIOGRAPHY; HEALTH CARE ORGANIZATION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HOSPITALIZATION; HUMAN; HYPOTENSION; MEDICAL SOCIETY; PATHOPHYSIOLOGY; PATIENT EDUCATION; PRIORITY JOURNAL; PROPHYLAXIS; QRS COMPLEX; RISK FACTOR; SELF CARE; SIDE EFFECT; STEM CELL TRANSPLANTATION; STROKE; SURGICAL PATIENT; T WAVE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AMERICAN HEART ASSOCIATION; ARRHYTHMIAS, CARDIAC; ATRIAL FIBRILLATION; CARDIAC PACING, ARTIFICIAL; CLINICAL TRIALS AS TOPIC; FLUOROBENZENES; HEART FAILURE; HUMANS; METOPROLOL; PYRIMIDINES; STEM CELL TRANSPLANTATION; SULFONAMIDES; UNITED STATES;

EID: 37549054650     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2007.12.004     Document Type: Article

References (37)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The long term intervention with pravastatin in ischemic heart disease (LIPID) study group. N Eng J Med 339 (1998) 1349-1357
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo controlled trial. Lancet 360 (2002) 7-22
4. Khush K.K., Waters D.D., Bittner V., et al. Effect of high-dose atorvastatin on hospitalizations for heart failure. Subgroup analysis of the treating to new targets (TNT) study. Circulation 115 (2007) 576-583
5. Loh P.H., Windram J.D., Tin L., et al. The effects of initiation or continuation of statin therapy on cholesterol level and all-cause mortality after the diagnosis of left ventricular systolic dysfunction. Am Heart J 153 (2007) 537-544
6. Kjekshus J., Pedersen T.R., Olsson A.G., et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 3 (1997) 249-254
7. Cleland J.G., Loh H., Windram J., Goode K., and Clark A.L. Threats, opportunities and statins in the modern management of heart failure. Eur Heart J 27 (2006) 641-643
8. Cleland J.G.F., Abdellah A.T., Khaleva O., et al. Clinical trials update from the European Society of Cardiology Congress 2007: 3CPO, ALOFT, SEARCH-MI, PROSPECT and Statins for Heart Failure. Eur J Heart Fail 9 (2007) 1070-1073
9. Rauchhaus M., Clark A.L., Doehner W., et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 42 (2003) 1933-1944
10. Kjekshus J., Dunselman P., Blideskog M., et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 7 (2005) 1059-1069
11. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Eng J Med 357 (2007) 2248-2261
12. Cleland J.G., Daubert J.G., Erdmann E., et al. The effect of cardiac resynchronisation therapy on morbidity and mortality in heart failure. N Eng J Med 352 (2005) 1539-1549
13. Heart Protection Study Collaborative Group. N-terminal pro-B-Type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF Heart Protection Study. J Am Coll Cardiol 49 (2007) 311-319
14. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1192-1197
15. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Eng J Med 353 (2005) 238-248
16. Cleland J.G. Is aspirin the "weakest link" in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Prog Cardiovasc Dis 44 (2002) 275-292
17. Tavazzi L., Tognoni G., Franzosi M.G., et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 6 (2004) 635-641
18. Beshai J.F., Grimm R.A., Nagueh S.F., et al. Cardiac-resynchronisation therapy in heart failure with narrow QRS complexes. N Eng J Med 357 (2007) 2461-2471
19. Cleland J.G.F., Abdellah A.T., Khaleva O., et al. Clinical trials update from the European Society of Cardiology Congress 2007: 3CPO, ALOFT, PROSPECT, and statins in heart failure. Eur J Heart Fail 9 (2007) 1070-1073
20. Swedberg K., Olsson L.G., Charlesworth A., et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J 26 (2005) 1303-1308
21. Hoppe U.C., Casares J.M., Eiskjaer H., et al. Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation 114 (2006) 18-25
22. Carlson M.D., Ip J., Messenger J., et al. A new pacemaker algorithm for the treatment of atrial fibrillation: results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT). J Am Coll Cardiol 42 (2003) 627-633
23. Wyse D.G., Waldo A.L., DiMarco J.P., et al. A comparison of rate control versus rhythm control in patients with atrial fibrillation. N Eng J Med 347 (2002) 1825-1833
24. VanGelder I.C., Hagens V.E., Bosker H.A., et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Eng J Med 347 (2002) 1834-1840
25. Coletta A., Thackray S., Nikitin N., and Cleland J.G.F. Clinical trials update: highlights of the scientific sessions of the American College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial, and HARDBALL. Eur J Heart Fail 4 (2002) 381-388
26. Torp-Pedersen C., Metra M., Spark P., et al. The safety of amiodarone in patients with heart failure. J Card Fail 13 (2007) 340-345
27. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Eng J Med 352 (2005) 225-237
28. Cleland J.G.F., Coletta A.P., Abdellah A.T., et al. Clinical trials update from the American Heart Association 2006: OAT, SALT 1 and 2, MAGIC, PABA-CHF, IMPROVE-CHF, and percutaneous mitral annuloplasty. Eur J Heart Fail 9 (2007) 92-97
29. Cleland J.G.F., Coletta A.P., and Clark A.L. Clinical trials update from the American College of Cardiology 2007: ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet. Eur J Heart Fail 9 (2007) 740-745
30. Eldh A.C., Ehnfors M., and Ekman I. The meaning of patient participation for patients and nurses at a nurse led clinic for chronic heart failure. Eur J Cardiovasc Nurs 5 (2006) 45-53
31. Cleland J.G.F., Coletta A.P., Abdellah A.T., et al. Clinical trials update from Heart Rhythm 2007 and Heart Failure 2007: CARISMA, PREPARE, DAVID II, SAVE-PACE, PROTECT and AREA-IN-CHF. Eur J Heart Fail 9 (2007) 850-853
32. Exner D.V., Kavanagh K.M., Slawnytch M.P., et al. Non-invasive risk assessment early after a myocardial infarction. The REFINE study. J Am Coll Cardiol 50 (2007) 2275-2284
33. Fleisher L.A., Beckman J.A., Brown K.A., et al. ACC/AHA 2007 Guidelines on perioperative cardiovascular evaluation and care for non-cardiac surgery; executive summary. Circulation 116 (2007) 1971-1996
34. Dib N., Michler R.E., Pagani F.D., et al. Safety and feasibility of autologous skeletal myoblast transplantation in patients with ischemic cardiomyopathy: four year follow-up. Circulation 112 (2005) 1748-1755
35. Cleland J.G.F., Freemantle N., Coletta A.P., and Clark A.L. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE II, SURVIVE and PROACTIVE. Eur J Heart Fail 8 (2006) 105-110
36. Lunde K., Solheim S., Aakhus S., et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Eng J Med 355 (2006) 1199-1209
37. Meyer G.P., Wlooert K.C., Lotz J., et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months follow-up data from the randomized, controlled BOOST trial. Circulation 113 (2006) 1287-1294